AD Pipeline Watch: CAGE Bio’s Topical CGB-500 Helps Patients Ditch Itch Early
CAGE Bio’s investigational atopic dermatitis (AD) drug CGB-500 outperformed efficacy benchmarks while meeting safety endpoints, according to topline results from a Phase 2b dose-ranging trial.